CARGO elects to discontinue FIRCE-1, a Phase 2 clinical study of firicabtagene autoleucel (firi-cel)1; Company believes results do not support a ...
Dr. Walker was most recently Chief Medical Officer of Harpoon Therapeutics through its acquisition by Merck in 2024 including leadership over its immune-oncology work. Prior to joining Harpoon ...
As we observe World Cancer Day today, let us look at some of the trends in cancer therapeutics expected to improve cancer ...
Terry Sejnowski is laboratory head of the computational neurobiology laboratory at the Salk Institute for Biological Studies ...
CAR T-cell therapies have established themselves as a frequently very successful and overall promising treatment option for various blood cancers for which no other effective therapies are available.
Cases of secondary tumors have been reported as a possible adverse reaction to the treatment of certain blood cancers with CAR T-cells. A recent analysis of the cases reported to the ...
The changes will extend the company's cash runway, enabling it to advance a tri-specific CAR T-cell candidate and its allogeneic cell therapy platform.
Choose from Car Wreck Ambulance stock illustrations from iStock. Find high-quality royalty-free vector images that you won't find anywhere else. Video Back Videos home Signature collection Essentials ...
Choose from Car Wreck Injury stock illustrations from iStock. Find high-quality royalty-free vector images that you won't find anywhere else. Video Back Videos home Signature collection Essentials ...
The T cells are activated with cytokines to stimulate cell division, and a viral vector is then used to engineer ... and is evaluating allogeneic CD19 CAR-T for autoimmune diseases”, said Mei. BRL ...
This expansion increases the vulnerability for vector-borne diseases such as dengue, chikungunya, Zika, Chagas disease, typhus, tick-borne relapsing fever and related human and veterinary illnesses.
Trenchant partnered with Autolomous, integrating its digital solution into its CGT manufacturing platform, for faster production and lower costs.